Hong Kong To Limit Tests, Antivirals To Those At High H1N1 Flu Risk
This article was originally published in PharmAsia News
Executive Summary
Hong Kong authorities have decided to limit tests and antiviral treatment for the H1N1 flu to patients considered at high risk for the disease. Clinicians are to determine those who should be treated, the Hong Kong Hospital Authority said. The tests and treatment are to be given to patients showing symptoms if they are under six years of age, pregnant or have chronic diseases, or have a persistent fever two days after symptomatic treatment. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.